UBS Group
ENTA icon

UBS Group’s Enanta Pharmaceuticals ENTA Stock Holding History

UBS Group’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-3,100
Closed -$158K – 8947
2014
Q4 		$158K Buy
+3,100
New +$139K ﹤0.01% 5261

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

UBS Group's ENTA Position: Q1 2026 in Review

UBS Group increased its Enanta Pharmaceuticals (ENTA) stake by 1,153% in Q1 2026, buying an estimated $787K and bringing the position to 63,804 shares worth $806K. The position accounts for ﹤0.01% of the portfolio, ranked #5718.

UBS Group first reported a position in ENTA in Q4 2014 and has held it in 45 quarters since. The position peaked at $3.02M in Q4 2021. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • UBS Group held 63,804 shares of Enanta Pharmaceuticals worth $806K as of Q1 2026.
  • UBS Group bought 58,712 Enanta Pharmaceuticals shares in Q1 2026, an estimated $787K.
  • Enanta Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5718 holding.
  • UBS Group first reported a position in Enanta Pharmaceuticals in Q4 2014 and has held it in 45 quarters since.
  • UBS Group's Enanta Pharmaceuticals position peaked at $3.02M in Q4 2021.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.